Telpegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in patients with high- or medium-risk non-myeloid malignancies: a multicenter, retrospective study
Telpegfilgrastim administered on the 2nd and 3rd day after chemotherapy effectively reduced the risk of CIN and FN. Besides this, primary prophylaxis is more beneficial.
Authors
- Hongming He
- Jia Li (ORCID: https://orcid.org/0000-0002-3108-8645)
- Qin Liao (ORCID: https://orcid.org/0000-0002-1935-4453)
- Yan Zhang (ORCID: https://orcid.org/0000-0002-6260-4737)
- Yanbing Zheng
Institutions
- Fujian Medical University (CN)
- Zhejiang Shuren University (CN)
- Jiangsu Cancer Hospital (CN)
- Henan Cancer Hospital (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1186/s12885-025-14911-5
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00